Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Bob Löwenberg’s perspective on CAR-T and immunotherapy for AML

Bob Löwenberg • 24 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Antibodies CAR-T

Bob Löwenberg, MD, PhD, of Erasmus University Medical Centre, Rotterdam, Netherlands, discusses his thoughts on CAR T-cell therapy and other immuno-oncology treatments for acute myeloid leukemia (AML). This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Bob Löwenberg

1:02
Azacitidine maintance to improve DFS in elderly AML: HOVON-97 results
Bob Löwenberg • 24 Feb 2019
3:46
Developments in newly diagnosed AML therapy in Europe: inspiring cooperation for tailored treatment
Bob Löwenberg • 24 Feb 2019
3:18
How can we tackle treatment failure in ALL?
Bob Löwenberg • 16 Apr 2018
4:57
The molecular heterogeneity of acute myeloid leukemia (AML) – new data and implications
Bob Löwenberg • 19 Feb 2017

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals